
Closing the gaps between vector design, manufacture, and patient access
To hear when each 2027 output is published
REGISTER YOUR INTERESTInterested in sponsoring the SIG?
FIND OUT MOREThe Cell & Gene Therapy Insights Viral Vectors Special Interest Group (SIG) is an invitation-only initiative that brings senior experts together in small, closed-door working groups under the Chatham House Rule to build consensus, set priorities, and produce practical, open-access guidance for the field.
SIG members are invited from pharma, biotech, contract development and manufacturing organizations (CDMOs), regulatory agencies, clinical practice, and academia to address one central question:
How can viral vector design, manufacture, and access be brought up to what the field now demands?

Viral vectors remain the delivery backbone of gene therapy, but the obstacles now sit across the full path from design to patient. Capsid engineering is extending tissue targeting while high systemic doses continue to raise safety limits. Analytical methods disagree on basic product attributes, and potency assays are built without a template. Manufacturing capacity and cost of goods decide which indications are viable long before a payer does, and approved products have underperformed commercially even where clinical benefit is clear.
This inaugural SIG brings those questions into a single forum. Members will address:
The steering committee and SIG members will be announced in 2027.
The SIG’s work in 2027 centers on a series of closed-door working groups, taking place from September 27 to October 15. The Cell & Gene Therapy Insights editorial team then turns the consensus reached by members into a series of outputs published in the months that follow, setting out the field’s shared position and priorities.
Inaugural annual SIG:
September 27 – October 15, 2027 (virtual)
The initiative is formed by a series of working groups over three weeks, each focused on a single priority topic.
Working groups will cover:
All SIG members meet under the Chatham House Rule. Each working group will produce consensus statements, which will form the basis of the outputs below.
A peer-reviewed white paper on a priority topic identified by the group.
An in-depth, open-access consensus report with strategic recommendations for the field.
These may include webinars, infographics, articles, in-person SIG member gatherings, and report-outs at major cell and gene therapy conferences.
To be kept informed about the progression and development of the SIG outputs, please register your interest.
REGISTER YOUR INTERESTTo hear when each 2027 output is published
REGISTER YOUR INTEREST